Dr Choo is the founder, CEO and CSO of Progenitor Therapeutics. He is also the founder of Plasticell Ltd, a leading stem cell technology and cell therapy company. Prior to his interest in stem cells he was a founder and Chief Scientist of Gendaq (1999-2001; acquired by Sangamo Biosciences), a biotech company that developed the zinc finger technology now used for gene editing. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge where he worked with Nobel laureate Professor Sir Aaron Klug. He serves on the UK Stem Cell Steering Committee, which oversees national stem cell research and the UK Stem Cell Bank.
Mr Saw is the COO of Progenitor Therapeutics, and CEO of its sister company Plasticell. He gained a first class degree in the life sciences from Imperial College, London, and subsequently trained at the Max-Planck Institute, Berlin, as part of the German human genome effort. After selling his first company, he worked at Goldman Sachs as an investment banker, executing corporate finance solutions and mergers and acquisitions deals for clients in Europe and the US. Mr. Saw is a serial entrepreneur, having co-founded a capital markets consultancy firm, a merchant bank and a securities research & brokerage house before turning his focus to Plasticell and Progenitor Therapeutics.